Regeneron Pharmaceuticals Inc
REGN
View Detailed Chart
751.130USD
-20.120-2.61%
Close 01/28, 16:00（ET）Quotes delayed by 15 min
79.09BMarket Cap
17.32P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.61%
5 Days
+0.24%
1 Month
-4.31%
6 Months
+34.46%
Year to Date
-2.69%
1 Year
+9.44%
View Detailed Chart
TradingKey Stock Score of Regeneron Pharmaceuticals Inc
Currency: USD Updated: 2026-01-28Key Insights
Regeneron Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 826.22.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regeneron Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Regeneron Pharmaceuticals Inc Highlights
StrengthsRisks
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.67% year-on-year.
Fairly Valued
The company’s latest PE is 17.32, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 93.40M shares, decreasing 2.51% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 735.00 shares of this stock.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
826.218
Target Price
+9.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Regeneron Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regeneron Pharmaceuticals Inc Info
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Ticker SymbolREGN
CompanyRegeneron Pharmaceuticals Inc
CEOSchleifer (Leonard S)
Websitehttps://www.regeneron.com/
Related Instruments
-1.51%
+1.46%
-2.35%
-2.49%
-2.86%
-0.95%
-4.07%
-2.59%
-0.89%
-2.42%
+0.79%
-3.62%
-1.69%
-0.91%
-1.38%
-1.06%
0.00%
-2.42%
-1.30%Popular Symbols
256.440
-1.830 (-0.71%)
191.520
+3.000 (+1.59%)
88258.170
-842.460 (-0.95%)
279.700
+27.040 (+10.70%)
2956.360
-53.340 (-1.77%)
431.460
+0.560 (+0.13%)
5552.850
+176.250 (+3.28%)
64.126
+0.909 (+1.44%)
1.199
+0.004 (+0.36%)
152.996
-0.381 (-0.25%)
